参考文献/References:
[1] Mcfaline-Figueroa JR, Lee EQ. Brain tumors[J]. Am J Med, 2018, 131(8): 874-882.
[2] Milde T, Kleber S, Korshunov A, et al. A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat[J]. Acta Neuropathol, 2011, 122(5): 637-650.
[3] Lester A, Mcdonald KL. Intracranial ependymomas: molecular insights and translation to treatment[J]. Brain Pathol, 2020, 30(1): 3-12.
[4] Davis S, Meltzer PS. GEOquery: a bridge between the Gene Expression Omnibus(GEO)and BioConductor[J]. Bioinformatics, 2007, 23(14): 1846-1847.
[5] Leek JT, Storey JD. Capturing heterogeneity in gene expression studies by surrogate variable analysis[J]. PLoS Genet, 2007, 3(9): 1724-1735.
[6] Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies[J]. Nucleic Acids Res, 2015, 43(7): e47.
[7] Yu G, Wang LG, Han Y, et al. Cluster profiler: an R package for comparing biological themes among gene clusters[J]. OMICS, 2012, 16(5):284-287.
[8] Liu Z, Yao Z, Li C, et al. Gene expression profiling in human high-grade astrocytomas[J]. Comp Funct Genomics, 2011, 2011: 245137.
[9] Koos B, Bender S, Witt H, et al. The transcription factor evi-1 is overexpressed, promotes proliferation, and is prognostically unfavorable in infratentorial ependymomas[J]. Clin Cancer Res, 2011, 17(11): 3631-3637.
[10] Henriquez NV, Forshew T, Tatevossian R, et al. Comparative expression analysis reveals lineage relationships between human and murine gliomas and a dominance of glial signatures during tumor propagation in vitro[J]. Cancer Res, 2013,73(18): 5834-5844.
[11] Vladoiu MC, El-Hamamy I, Donovan LK, et al. Childhood cerebellar tumours Mirror conserved fetal transcriptional programs[J]. Nature, 2019, 572(7767): 67-73.
[12] Griesinger AM, Josephson RJ, Donson AM, et al. Interleukin-6/STAT3 pathway signaling drives an inflammatory phenotype in group a ependymoma[J]. Cancer Immunol Res, 2015, 3(10): 1165-1174.
[13] De Bont JM, Kros JM, Passier MM, et al. Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis[J]. Neuro Oncol, 2008, 10(5): 648-660.
[14] Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system[J]. Acta Neuropathol, 2007, 114(2): 97-109.
[15] Rodríguez D, Cheung MC, Housri N, et al. Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the Surveillance, Epidemiology, and End Results(SEER)database(1973-2005)[J]. J Surg Res, 2009, 156(2): 340-351.
[16] Mack SC, Pajtler KW, Chavez L, et al. Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling[J]. Nature, 2018, 553(7686): 101-105.
[17] Shen R, Chinnaiyan AM, Ghosh D. Pathway analysis reveals functional convergence of gene expression profiles in breast cancer[J]. BMC Med Genomics, 2008, 1: 28.
[18] Mack SC, Witt H, Piro RM, et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy[J]. Nature, 2014, 506(7489): 445-450.
[19] Suarez-Merino B, Hubank M, Revesz T, et al. Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3[J]. Neuro Oncol, 2005, 7(1): 20-31.
[20] Wang J, Sun C, Liu M, et al. The potentially therapeutic targets of pediatric anaplastic ependymoma by transcriptome profiling[J]. Neoplasma, 2021, 68(1): 53-61.
[21] Park Y, Ryu JK. Models of synaptotagmin-1 to trigger Ca2+-dependent vesicle fusion[J]. FEBS Lett, 2018, 592(21): 3480-3492.
[22] Sun J, Wang L, Bao H, et al. Functional cooperation of α-synuclein and VAMP2 in synaptic vesicle recycling[J]. Proc Natl Acad Sci U S A, 2019, 116(23): 11113-11115.
[23] Foo JN, Tan LC, Au WL, et al. No association of DNM3 with age of onset in Asian Parkinson’s disease[J]. European Journal of Neurology, 2019, 26(5): 827-829.
[24] Pan F, Chen M, Song XY, et al. MicroRNA-301b and its target gene synaptosome-associated protein 91 as important modulators in esophageal cancer: functional experiments[J]. Anticancer Drugs, 2020, 31(4): 411-422.
[25] Sinha S, Chunder N, Mukherjee N, et al. Frequent deletion and methylation in SH3GL2 and CDKN2A loci are associated with early- and late-onset breast carcinoma[J]. Ann Surg Oncol, 2008, 15(4): 1070-1080.
[26] Dasgupta S, Jang JS, Shao CB, et al. SH3GL2 is frequently deleted in non-small cell lung cancer and downregulates tumor growth by modulating EGFR signaling[J]. Journal of Molecular Medicine - JMM, 2013, 91(3): 381-393.
[27] Zhang H, Liu Y, Xu K, et al. AMPH-1 as a critical tumor suppressor that inhibits osteosarcoma progression[J]. Cancer Manag Res, 2019, 11: 9913-9919.
[28] Yang H, Wan Z, Huang C, et al. AMPH-1 is a tumor suppressor of lung cancer by inhibiting Ras-Raf-MEK-ERK signal pathway[J]. Lasers Med Sci, 2019, 34(3): 473-478.
[29] Chen Y, Liu J, Li L, et al. AMPH-1 is critical for breast cancer progression[J]. J Cancer, 2018, 9(12): 2175-2182.
[30] Rao B, Gao Y, Huang J, et al. Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis[J]. Int J Colorectal Dis, 2011, 26(5): 593-601.
[31] Olgiati S, Quadri M, Fang M, et al. DNAJC6 mutations associated with Early-Onset parkinson’s disease[J]. Ann Neurol, 2016, 79(2): 244-256.
[32] Yang T, Li XN, Li XG, et al. DNAJC6 promotes hepatocellular carcinoma progression through induction of epithelial-mesenchymal transition[J]. Biochem Biophys Res Commun, 2014, 455(3/4): 298-304.
[33] Konstantinopoulos PA, Vandoros GP, Papavassiliou AG. FK228(depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities[J]. Cancer Chemother Pharmacol, 2006, 58(5): 711-715.
[34] Tzaridis T, Milde T, Pajtler KW, et al. Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma[J]. Oncotarget, 2016, 7(38): 61860-61873.
[35] Misra RN, Xiao HY, Kim KS, et al. N-(Cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2.N-
[5-[[
[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide(BMS-387032), a highly efficacious and selective antitumor agent[J]. J Med Chem, 2004,47(7): 1719-28.
[36] Li C, Dong L, Su R, et al. Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC[J]. Haematologica, 2020, 105(1): 148-160.